Research outlook

Where primary CNS lymphoma treatment is heading

Primary CNS lymphoma · Updated Nov 14, 2026

Primary central nervous system lymphoma (PCNSL) is an aggressive lymphoma that starts in the brain, spinal cord, eyes or spinal fluid, without disease elsewhere. About 1,500 Americans are diagnosed each year, most over 60. Treatment starts with high-dose methotrexate-based chemotherapy, followed by consolidation to prevent relapse. A large 2026 trial confirmed stem-cell transplant as the best consolidation for fit patients, and BTK inhibitor pills that reach the brain are moving toward approval and into first-line treatment.

  1. Now

    Nov 2026

    Transplant is the best consolidationHappened 78% 3-year progression-free

    After MATRix induction, transplant gave 78% 3-year progression-free survival vs 51% with further chemotherapy.

    78%: 3-year progression-free with transplant, vs 51%.

    Low-dose radiation as an alternativeHappened 78.7% 2-year progression-free

    Adding low-dose brain radiation to chemotherapy raised 2-year progression-free survival to 78.7% vs 54%, without measurable harm to thinking.

    78.7%: 2-year progression-free with low-dose radiation, vs 54%.

    BTK inhibitors work in the brainHappened 73% response rate

    Across 40 studies, BTK inhibitors shrank CNS lymphoma in 73% of patients.

    73%: pooled response rate.

  2. 6 months

    by May 2027

    FDA decision on tirabrutinibLikely 67% response rate

    The FDA is due to decide by December 18, 2026, on tirabrutinib for relapsed PCNSL (67% response rate).

    67%: response rate.

  3. 12 months

    by Nov 2027

    Confirming tirabrutinibPossible

    Ono's IGNITE (132 people) compares tirabrutinib with rituximab-temozolomide; due December 2027.

  4. 3 years

    by late 2029

    Less intensive inductionPossible

    OptiMATe (331 people) tests shorter induction; due June 2028.

    BTK inhibitors in first-line treatmentPossible 87.1% complete response (phase 2)

    A Chinese phase 3 adds orelabrutinib to first-line chemotherapy (215 people, due September 2028).

    87.1%: complete response after induction.

    CAR T cellsLong shot

    A liso-cel trial adds CAR T cells to first-line treatment (65 people, due January 2028).

  5. 5 years

    by late 2031

    Transplant for older patientsPossible 78% 3-year progression-free (under 70)

    PRIMA-CNS (340 people) tests adjusted-dose transplant in older patients; due August 2029.

    78%: 3-year progression-free with transplant, vs 51%.

Happened Likely Possible Long shot

The research paths

Rising

BTK inhibitors

67% response rate
Details and 3 trialsHide
Active

Consolidation strategy

78% 3-year progression-free
Details and 2 trialsHide
Early

Cell therapy

Details and 1 trialsHide

CAR T cells for relapsed and high-risk disease.

WatchLiso-cel first-line trial.

Borrowed from other cancers

From CLL and other B-cell lymphomas

Tirabrutinib and other BTK inhibitors

Under FDA review

BTK inhibitors developed for systemic lymphomas that also cross into the brain.

From Diffuse large B-cell lymphoma

Liso-cel

Phase 2

A CD19 CAR T-cell therapy approved for lymphomas outside the brain.

From Multiple myeloma

Lenalidomide

Phase 2

An immune-modulating pill tested with ibrutinib for maintenance.

Open to join now

See every recruiting PCNSL trial →

When the trials finish

Completion dates the trials registered. Results usually follow 3 to 12 months later.

2026202720282029203020312032Today

What just happened

Transplant beats chemotherapy as consolidation

MATRix/IELSG43, The Lancet.

FDA accepts tirabrutinib application

PROSPECT; decision due December 2026.

Standard treatment today

How to read this page, and sourcesHow to read this page, and sources

See PCNSL trials recruiting now →

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.